We are live on
!
Find out more
Lazard Asset Management Portfolio holdings
AUM
$60.8B
1-Year Est. Return
22.47%
This Fund
S&P 500
This Quarter
Est. Return
+5.89%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+302.07%
AUM
$47.8B
AUM Growth
+$3.07B
(+6.9%)
Cap. Flow
-$507M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
17.74%
Holding
1,131
New
130
Increased
292
Reduced
306
Closed
143
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$526M |
| 2 |
Ally Financial
ALLY
|
+$198M |
| 3 |
CSX Corp
CSX
|
+$191M |
| 4 |
NetEase
NTES
|
+$173M |
| 5 |
Norwegian Cruise Line
NCLH
|
+$171M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$262M |
| 2 |
CVS Health
CVS
|
+$240M |
| 3 |
Mastercard
MA
|
+$204M |
| 4 |
McKesson
MCK
|
+$201M |
| 5 |
Molson Coors Class B
TAP
|
+$171M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 14.83% |
| 2 | Communication Services | 13.94% |
| 3 | Technology | 12.15% |
| 4 | Financials | 10.5% |
| 5 | Energy | 9.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
JPMorgan Chase
JPM
$946B
| $45.6M | 0.1% |
791,159
+6,094
| +0.8% | +$343K |
|
|
HMHC
177
DELISTED
Houghton Mifflin Harcourt Company
HMHC
| $45.2M | 0.09% |
2,360,912
+1,251,462
| +113% | +$24.2M |
|
178
Freeport-McMoran
FCX
$89.8B
| $45.1M | 0.09% |
1,235,633
+68,713
| +6% | +$2.35M |
|
179
Thermo Fisher Scientific
TMO
$210B
| $44.4M | 0.09% |
376,606
+14,295
| +4% | +$1.68M |
|
180
Banco Macro
BMA
$5.81B
| $43.1M | 0.09% |
1,196,376
-365,165
| -23% | -$11.7M |
|
181
Ameren
AEE
$31.3B
| $43M | 0.09% |
+1,051,923
| New | +$41.9M |
|
182
NCR Voyix
VYX
$1.13B
| $41.8M | 0.09% |
+1,941,279
| New | +$39.2M |
|
|
SBNY
183
DELISTED
Signature Bank
SBNY
| $41.3M | 0.09% |
327,217
+170,849
| +109% | +$20.5M |
|
|
TWN
184
Taiwan Fund
TWN
$483M
| $41M | 0.09% |
1,999,140
-51,184
| -2% | -$991K |
|
185
XPO
XPO
$24.2B
| $40.9M | 0.09% |
4,135,003
+405,449
| +11% | +$3.7M |
|
186
Crown Holdings
CCK
$12.9B
| $38.7M | 0.08% |
778,029
+64,550
| +9% | +$3.1M |
|
|
LVLT
187
DELISTED
Level 3 Communications Inc
LVLT
| $37.7M | 0.08% |
857,804
| – | – |
|
188
Texas Instruments
TXN
$254B
| $37.2M | 0.08% |
777,567
-1,094,893
| -58% | -$51.1M |
|
|
GLO
189
Clough Global Opportunities Fund
GLO
$249M
| $36.9M | 0.08% |
2,837,338
-780,703
| -22% | -$9.89M |
|
190
Lumen
LUMN
$6.45B
| $36.8M | 0.08% |
1,016,440
+7,887
| +0.8% | +$283K |
|
|
ETW
191
Eaton Vance Tax-Managed Global Buy-Write Opportunities Fund
ETW
$1.02B
| $36M | 0.08% |
2,821,770
-224,500
| -7% | -$2.8M |
|
192
iShares Core S&P Mid-Cap ETF
IJH
$123B
| $36M | 0.08% |
1,257,215
-34,220
| -3% | -$940K |
|
193
ConocoPhillips
COP
$143B
| $35.7M | 0.07% |
416,511
+86,945
| +26% | +$6.77M |
|
194
Rogers Communications
RCI
$17.7B
| $34.8M | 0.07% |
863,955
+35,629
| +4% | +$1.44M |
|
195
Walmart Inc
WMT
$889B
| $34.4M | 0.07% |
1,375,800
-691,851
| -33% | -$17.8M |
|
|
LAQ
196
DELISTED
Aberdeen Latin America Equity Fund
LAQ
| $33.3M | 0.07% |
1,114,135
-985
| -0.1% | -$28.8K |
|
197
GE Aerospace
GE
$372B
| $33.1M | 0.07% |
263,126
-20,016
| -7% | -$2.55M |
|
|
EMF
198
Templeton Emerging Markets Fund
EMF
$311M
| $32.5M | 0.07% |
1,781,982
-127,480
| -7% | -$2.27M |
|
|
CVG
199
DELISTED
Convergys
CVG
| $32.4M | 0.07% |
1,513,070
+19,916
| +1% | +$432K |
|
|
PEGI
200
DELISTED
Pattern Energy Group Inc. Class A
PEGI
| $32.3M | 0.07% |
975,148
+43,876
| +5% | +$1.28M |
|
Similar funds
QCM
Lazard Asset Management's Q2 2014 Portfolio in Review
As of Q2 2014, Lazard Asset Management held 1,131 positions worth $47.8B, up 6.9% from $44.8B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Lazard Asset Management's Q2 2014 filing shows 130 new, 292 increased, 306 reduced and 143 closed positions. Its largest new stake was Ally Financial: 8,153,883 shares worth $195M. The largest sale was Gilead Sciences, an estimated $262M.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 16% a quarter earlier, followed by Communication Services and Technology.
- Lazard Asset Management's largest Q2 2014 buy was Ally Financial: 8,153,883 shares worth $195M.
- Lazard Asset Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $526M increase.
- Lazard Asset Management's biggest Q2 2014 reduction was Gilead Sciences, cutting an estimated $262M.
- Lazard Asset Management fully exited Mastercard in Q2 2014, selling an estimated $204M.
- Lazard Asset Management's ten largest holdings make up 18% of its $47.8B portfolio in Q2 2014.
- Lazard Asset Management opened 130 new positions and closed 143 in Q2 2014.
- Lazard Asset Management's portfolio value rose 6.9% quarter-over-quarter to $47.8B.
Based on Lazard Asset Management's 13F filing for Q2 2014, filed 12 Aug 2014.